ABCG2 and cancer: Moreover, several challenges reduce chemotherapeutic efficacy and enhance developing cancer cell resistance toward paclitaxel, including ABC transporter, P-glycoprotein, MDR-associated protein (MRP1), and breast cancer resistance protein (BCRP), as shown in Fig. 5.